Next Article in Journal
The Need for Clinical Decision Support Integrated with the Electronic Health Record for the Clinical Application of Whole Genome Sequencing Information
Previous Article in Journal
Attitudes towards Social Networking and Sharing Behaviors among Consumers of Direct-to-Consumer Personal Genomics
Previous Article in Special Issue
Structured Decision-Making: Using Personalized Medicine to Improve the Value of Cancer Care
J. Pers. Med. 2013, 3(4), 288-305; doi:10.3390/jpm3040288
Review

Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned

1,* , 2
,
3
,
3
 and
3
1 Office of Health Economics, London SW1E 6QT, UK 2 Novartis Pharma AG, Novartis Campus, Basel CH-4002, Switzerland 3 Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
* Author to whom correspondence should be addressed.
Received: 8 October 2013 / Revised: 18 October 2013 / Accepted: 18 October 2013 / Published: 25 October 2013
View Full-Text   |   Download PDF [388 KB, uploaded 25 October 2013]

Abstract

Ten years after completion of the Human Genome Project, progress towards making “personalized medicine” a reality has been slower than expected. The reason is twofold. Firstly, the science is more difficult than expected. Secondly, limited progress has been made in aligning economic incentives to invest in diagnostics. This paper develops nine case studies of “success” where diagnostic tests are bringing personalized medicine into clinical practice with health and economic impact for patients, healthcare systems, and manufacturers. We focus on the availability of evidence for clinical utility, which is important not only for clinicians but also for payers and budget holders. We find that demonstrating diagnostic clinical utility and the development of economic evidence is currently feasible (i) through drug-diagnostic co-development, and (ii) when the research is sponsored by payers and public bodies. It is less clear whether the diagnostic industry can routinely undertake the work necessary to provide evidence as to the clinical utility and economic value of its products. It would be good public policy to increase the economic incentives to produce evidence of clinical utility: otherwise, opportunities to generate value from personalized medicine—in terms of both cost savings and health gains—may be lost.
Keywords: diagnostics; companion-diagnostics; personalized medicine; clinical utility; economic value; decision-making diagnostics; companion-diagnostics; personalized medicine; clinical utility; economic value; decision-making
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Towse, A.; Ossa, D.; Veenstra, D.; Carlson, J.; Garrison, L. Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned. J. Pers. Med. 2013, 3, 288-305.

View more citation formats

Related Articles

Article Metrics

Comments

Cited By

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert